Skip to main content

Table 4 RFS in patients with a HR-positive or HR–negative tumor classified by clinical and genetic characteristics

From: Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

 

Hormone receptor-positive tumors (n=25)

Hormone receptor-negative tumors (n=17)

 

No. of Patients (No. of events)

3-year estimates

95% CI

P-value

No. of Patients (No. of events)

3-year estimates

95% CI

P-value

All patients

25 (7)

0.76

0.58-0.95

 

17 (5)

0.69

0.42-0.95

 

Response to neoadjuvant CT

        

 pCR (grade 3)

8 (1)

0.81

0.58-1.05

0.485

12 (3)

1.0

-

0.906

 No pCR (grade 0~2)

14(4)

0.77

0.49-1.05

 

3 (1)

0.69

0.39-0.99

 

HER2 copy numbers

        

 ≤ 2.0

6 (4)

0.60

0.17-1.03

0.12

2 (1)

0.50

−0.19-1.19

NA

 > 2.0

19 (3)

0.81

0.62-1.01

 

15 (4)

0.74

0.47-1.00

 

Wild-type HER2 mRNA

        

 < 400

14 (5)

0.67

0.43-0.91

0.054

6 (3)

0.33

−0.17-0.83

0.196

 ≥ 400

6 (0)

1.0

-

 

11 (2)

0.86

0.60-1.12

 

∆16HER2 mRNA

        

 < 4.5

14 (4)

0.74

0.53-0.96

0.283

3 (1)

0

0

0.832

 ≥ 4.5

6 (1)

0.80

0.45-1.15

 

14 (4)

0.72

0.45-1.00

 

Percentages of ∆16HER2 mRNA

        

 < 2.4%

17 (3)

0.78

0.59-0.97

0.143

14 (3)

0.77

0.49-1.00

0.073

 ≥ 2.4%

3 (2)

0.67

0.13-1.20

 

3 (2)

0.33

−0.20-0.87

 

PIK3CA (exons 9 and 20)

        

 Wild-type

21 (4)

0.89

0.75-1.03

0.006

15 (5)

0.65

0.37-0.94

NA

 Mutated

4 (3)

0.25

−0.17-0.67

 

2 (0)

1.0

-

 

PIK3CA (exons 9 and 20)

        

 Wild-type + Norma l+ Loss +UPD

16 (1)

1.0

-

0.001

12 (5)

0.57

0.25-0.89

0.2

 Mutated + Gain

9 (6)

0.40

0.06-0.74

 

5 (0)

1.0

-

 

PTEN

        

 Normal + Gain + UPD

20 (6)

0.76

0.55-0.97

0.814

17 (5)

0.69

0.42-0.95

NA

 Loss

5 (1)

0.80

0.45-1.15

 

0

-

-

 

INPP4B

        

 Normal + Gain + UPD

21 (4)

0.83

0.65-1.01

0.133

15 (4)

0.75

0.49-1.00

NA

 Loss

4 (3)

0.50

0.01-0.99

 

2 (1)

0.50

−0.19-1.19

 

PI3KCA, PTEN, INPP4B

        

 No aberrations*

12 (0)

1.0

-

0.002

10 (4)

0.59

0.23-0.95

0.312

 Aberrations**

13 (7)

0.60

0.32-0.87

 

7 (1)

0.75

0.33-1.17

 

DEK

        

 Normal

17 (3)

0.86

0.68-1.04

0.067

11 (2)

0.91

0.74-1.08

0.106

 Gain

8 (4)

0.51

0.11-0.91

 

6 (3)

0.30

−0.17-0.77

 

FGFR1

        

 Normal + Loss + UPD

17 (5)

0.72

0.49-0.96

0.94

12 (4)

0.59

0.28-0.91

0.69

 Gain

8 (2)

0.86

0.60-1.12

 

5 (1)

1.0

-

 

CCND1

        

 Normal + Loss

16 (2)

0.91

0.74-1.08

0.075

9 (2)

0.71

0.36-1.06

0.433

 Gain

9 (5)

0.51

0.16-0.85

 

8 (3)

0.67

0.29-1.04

 

FOXA1

        

 Normal + UPD

17 (1)

0.92

0.76-1.07

0.002

13 (5)

0.66

0.39-0.93

0.504

 Gain

8 (6)

0.45

0.08-0.82

 

4 (0)

1.0

-

 

CDH3

        

 Normal + Loss + UPD

20 (3)

0.88

0.73-1.04

0.007

17 (5)

0.69

0.42-0.95

NA

 Gain

5 (4)

0.40

−0.03-0.83

 

0

-

-

 

BIRC5

        

 Normal + Loss + UPD

19 (3)

0.86

0.68-1.04

0.016

8 (2)

0.75

0.45-1.05

0.235

 Gain

6 (4)

0.44

0.01-0.88

 

9 (3)

0.59

0.10-1.09

 

MYBL2

        

 Normal + Loss

16 (2)

0.92

0.78-1.07

0.015

14 (5)

0.66

0.39-0.94

0.539

 Gain

9 (5)

0.48

0.11-0.84

 

3 (0)

1.0

-

 

AIB1

        

 Normal + Loss

17 (2)

0.93

0.79-1.06

0.006

14 (5)

0.66

0.39-0.94

0.539

 Gain

8 (5)

0.39

−0.01-0.78

 

3 (0)

1.0

-

 
  1. CI, confidence interval; CT, chemotherapy; NA, not applicable; *No aberrations, wild-type and a normal copy of PIK3CA, a normal copy, gain, or UPD of PTEN or INPP4B; **Aberrations, mutated and/or gain of PIK3CA, and loss of PTEN or INPP4B.